Abstract 2039P
Background
Reliable and validated primary endpoints, such as overall survival (OS), are commonly used in oncologic confirmatory randomized controlled trials (RCTs). However, recent studies suggest that these endpoints may not sufficiently measure the true benefits of therapies in older patients with cancer. We conducted a scoping review of the literature to identify primary endpoints used in geriatric oncology RCTs.
Methods
We searched the literature on confirmatory RCTs specific to older patients with cancer using PubMed (National Center for Biotechnology Information) and CINAHL (EBSCO). Studies fulfilling the selection criteria were reviewed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews, and definitions of primary endpoints were extracted.
Results
A total of 68 RCTs met the inclusion criteria. Data on geriatric assessment and quality of life (QOL) were extracted in 66 (97.1%) and 25 (36.8%) RCTs, respectively. Fifty-two RCTs (76.5%) used traditional outcomes, such as OS, DFS, relapse-free survival, progression-free survival, and response rate, as primary endpoints; however, one RCT used OS adjusted for QOL as a primary endpoint and one RCT used OS and health-related QOL as a combination primary endpoint. Three of the four RCTs using time-to-event endpoint as the primary endpoint included toxic effect as an event in addition to disease progression and death due to any cause. Toxic effect was a primary outcome measure in six RCTs (8.8%) which utilized the National Cancer Institute Common Terminology Criteria for Adverse Events. Health-related QOL, including the EORTC QOL Questionnaire core version 30 items, was a primary endpoint in three RCTs (4.4%). Barthel index for activities of daily living and the confusion assessment method for delirium were used in two RCTs (2.9%).
Conclusions
Although most geriatric oncology RCTs used traditional primary endpoints, some RCTs utilized innovative primary endpoints to more appropriately measure treatment benefit for older patients with cancer. This scoping review should be helpful for methodological discussions among investigators and efficient use of these endpoints.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06